Out For Tender

Out For TenderStati UnitiApparecchiature mediche, prodotti farmaceutici e per la cura personale

Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Stazione appaltante
DEFENSE HEALTH AGENCY, Dept of Defense
Paese
Stati Uniti
Categoria
Apparecchiature mediche, prodotti farmaceutici e per la cura personale
Scadenza
Scade oggi (24 Sep 2026 12:00 UTC-5)
Pubblicata
3 Sep 2026
Procedura
Solicitation - No Set aside used

Leggi il bando ufficiale e partecipa → La presentazione delle offerte avviene sempre sul portale della stazione appaltante, mai qui.

Che cosa richiede la stazione appaltante

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Furoscix ReadyFlow – Diuretics – NA b. Gwyn Lo – Contraceptive Agents – Miscellaneous c. Jideytro – Lung Cancer – NA d. Omlyclo – Atopy – NA e. RizaFilm – Migraine Agents – NA f. Zenbexus – Multiple Myeloma – NA The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9403. Pre-Quotation Teleconference is on September 9, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.

Lingua di questo bando: English. Titolo e descrizione sono mostrati esattamente come pubblicati dalla stazione appaltante.

Source: SAM · reference HT9402-26-Q-9403 · JSON